Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy

Qian Gou; Xin Gong; Jianhua Jin; Juanjuan Shi; Yongzhong Hou

doi:10.18632/oncotarget.19610

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy

Qian Gou, Xin Gong, Jianhua Jin, Juanjuan Shi and Yongzhong Hou _

PDF | HTML | How to cite

Oncotarget. 2017; 8:60704-60709. https://doi.org/10.18632/oncotarget.19610

Metrics: PDF 2142 views | HTML 5480 views | ?

Abstract

Qian Gou1,2,*, Xin Gong2,*, Jianhua Jin1,*, Juanjuan Shi2 and Yongzhong Hou1,2

1Department of Oncology, Affiliated Wujin People’s Hospital, Jiangsu University, Changzhou, 212017, PR China

2Institute of Life Sciences, Jiangsu University, Zhenjiang, 212013, PR China

*These authors contributed equally to this work

Correspondence to:

Yongzhong Hou, email: [email protected]

Keywords: PPARs, ligands, cancer therapy, cell signaling

Received: March 04, 2017 Accepted: July 18, 2017 Published: July 27, 2017

ABSTRACT

Peroxisome-proliferator-activated receptors (PPARs) are nuclear hormone receptors including PPARα, PPARδ and PPARγ, which play an important role in regulating cancer cell proliferation, survival, apoptosis, and tumor growth. Activation of PPARs by endogenous or synthetic compounds regulates tumor progression in various tissues. Although each PPAR isotype suppresses or promotes tumor development depending on the specific tissues or ligands, the mechanism is still unclear. In this review, we summarized the regulative mechanism of PPARs on cancer progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19610

Publication Alerts

Reviews:

Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy

Abstract